Daxor Corporation (NASDAQ:DXR) Sees Large Growth in Short Interest

Daxor Corporation (NASDAQ:DXR) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 6,959 shares, an increase of 198.5% from the September 15th total of 2,331 shares. Based on an average daily volume of 38,746 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the company’s stock are sold short.

Hedge Funds Weigh In On Daxor

Several large investors have recently bought and sold shares of DXR. Aristides Capital LLC bought a new position in shares of Daxor during the 1st quarter valued at about $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Daxor during the first quarter valued at approximately $245,000. Susquehanna International Group LLP boosted its holdings in Daxor by 97.7% during the second quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after buying an additional 13,411 shares in the last quarter. Finally, Crescent Grove Advisors LLC bought a new stake in Daxor during the first quarter worth approximately $104,000. Institutional investors and hedge funds own 1.34% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Daxor Stock Up 0.7%

Shares of DXR stock traded up $0.07 during trading hours on Tuesday, reaching $10.38. The stock had a trading volume of 16,010 shares, compared to its average volume of 11,496. Daxor has a twelve month low of $8.56 and a twelve month high of $14.76. The firm has a 50-day simple moving average of $10.59 and a 200-day simple moving average of $10.38.

Daxor Company Profile

Daxor Corporation (NASDAQ: DXR) is a medical device company focused on blood-volume measurement and related diagnostic technologies. Its principal product is the BVA-100 Blood Volume Analyzer, which uses an analysis of a blood sample containing a tracer to measure a patient’s total blood volume, plasma volume and red blood cell volume.

The company’s technology is designed to help clinicians assess fluid status and guide treatment decisions in settings such as heart failure, critical care, surgery, trauma and dialysis.